Rheumatology and rheumatoid arthritis constitute one of our areas of greater history and expertise. In 2004 we introduced the first injectable methotrexate on the market: Metoject®. This event marked a milestone within the therapeutic area, given that at the time in Spain methotrexate was only available orally. Ever since then, we have always been at the forefront of this market taking chances on innovation year after year. We have done this by introducing different improvements to the devices, incorporating new indications and launching new devices, formats and doses, such as the safety device of the prefilled syringe, the pack of 4 in 2017, or the prefilled subcutaneous methotrexate pen in January 2018.
Following this line of work, in 2022 we launched Jiax® Semanal, the first 2 mg/ml methotrexate oral solution available in Spain for the treatment of juvenile idiopathic arthritis.
In addition to Metoject®, Gebro Pharma also markets in Spain leflunomide for active rheumatoid arthritis and active psoriatic arthritis in adult patients.
Since January 2018 the rheumatology area counts with Videsil®, a Vitamin D in oral solution of cholecalciferol. Videsil® covers both the prevention and treatment of vitamin D deficiency, as well as adjuvant treatment of osteoporosis.
